Potential Benefits of Heterologous Mixture of COVID 19 Vaccinations from Different Manufacturers

By

Hasan Al Reza Pranto
16346005

A thesis submitted to the Department of Pharmacyin partial fulfillment of the requirements for the degree of
Bachelor of Pharmacy

Department of pharmacy
BRAC University
[December] [2021]

Declaration

It is hereby declared that

1. The thesis submitted is my/our own original work while completing degree at Brac University.
2. The thesis does not contain material previously published or written by a third party, except where this is appropriately cited through full and accurate referencing.
3. The thesis does not contain material which has been accepted, or submitted, for any other degree or diploma at a university or other institution.
4. I/We have acknowledged all main sources of help.

Student's Full Name & Signature:



Hasan Al Reza Pranto

Student ID -16346005

Approval

The thesis/project titled "Potential Benefits of Heterologous Mixture of COVID 19 Vaccinations from Different Manufacturers'; submitted by Hasan Al Reza Pranto (16346005) of Summer, 2020 has been accepted as satisfactory in partial fulfillment of the requirement for the degree of Bachelor of Pharmacy (Hons.) On [Date-of-Defense].

Examining Committee:

Supervisor:
(Member)

_____

Dr. Afrina Afrose,
Assistant Professor, Department of Pharmacy
Brac University

Program Coordinator:
(Member)

_____

Dr. Hasina Yeasmin
Associate Professor, Department of Pharmacy
Brac University

Departmental Head:
(Chair)

_____

Professor Dr. Eva Rahman Kabir
Chairperson, Department of Pharmacy
Brac University

Ethics Statement

No animal or human being was harmed during this work.

Abstract

The ongoing COVID-19 pandemic has been going on since 2019 and has spread throughout the world's region. To fight of COVID-19 virus, different vaccine Manufacturer Company has come up with different types of vaccines that include AstraZeneca, Pfizer/BNT Moderna, Sinovac etc. Vaccines are comprised of two vaccine regimens, the initial dose as prime dose and the second dose shot as a booster dose. A booster dose is important to produce enough antibodies to neutralize the COVID-19 virus. In the meantime, the virus has mutated several times and became more deadly. This study finds that a better immune response can be generated if two different types of vaccines are mixed and used as an initial and second dose. The immune system produces more virus-killing antibodies than single-brand vaccines used as an initial and subsequent dose. The side effects of such vaccination are found quite normal. The issue of vaccine shortage can also be overcome by such mixed vaccination. Some countries have failed to secure the buy of a single brand vaccine in large numbers, they can provide the second and further doses with the vaccine they have in their inventory in such vaccination procedure. They will have an option to provide a second dose with a different brand vaccine if they face any potential vaccine shortage. Heterologous vaccination will prove additional security from the new and deadly COVID-19 variants with enhanced immune protection as interpreted by some research.

Heterologous vaccination, Neutralizing- antibody, Mutation, Prime dose, Booster dose.

Acknowledgement

I would like to show my gratitude and respect to my honorable project supervisor Afrina Afrose, PhD, she has guided me, inspired me and helped me to complete my project. She has helped me and inspired me to overcome all the obstacles I faced. Without her guidance and help this project would not be possible.

All the praises go to almighty Allah as without his good grace I would not be able to make this far. Also I would like to show my heartiest respect to all of my honorable teachers of Department of Pharmacy, especially Professor Dr. Eva Rahman Kabir, Chairperson, Department of Pharmacy, Brac University, for all the teachings, support and love they gave me to achieve my goal.

Dedication

I dedicate this final year project work to my Mother Daizy Akter and Father Md Yousuf .

Table of Contents

List of Tables

List of figures

List of acronyms

RTPCR: The COVID-19 RT-PCR Test is a real-time reverse transcription polymerase chain reaction (rRT-PCR) test for the qualitative detection of nucleic acid from SARS-CoV-2 in upper and lower respiratory specimens.

NVX-CoV2373: Novovax COVID-19 vaccine.

ChAdOx1 nCoV-19: AstraZeneca Oxford Covid19 vaccine.

GMT: Geometric Mean Titer.

Chapter 1

Introduction

1.1Background

COVID-19 situation is getting worse day by day. Scientists have come up with plans to accelerate the COVID-19 vaccination process. Some studies had shown that heterologous mixture and application of COVID-19 from different sources can be done. Such vaccination will not be problematic (Brusso, 2021). Countries like Germany are allowing such vaccination. This idea looks promising to overcome the COVID-19 pandemic. Vaccination from multiple sources for booster dose can provide an additional boost to the immune system. Some countries have seen cases like people were affected with COVID-19 despite providing 1st dose of vaccine. In such cases, vaccines of different brands can be provided as a booster dose. A mixture of vaccines from different sources such as AstraZeneca / Pfizer / Moderna and other blends can be used (Moeira, 2021). Also due to vaccine manufacturers countries are storing a large proportion of vaccines and countries that cannot do so are facing vaccine shortages. Almost 90% of African nations are set to miss the worldwide objective of immunizing 10% of their kin by September, as per the World Health Organization. One serious issue is that COVAX, the UN-sponsored undertaking to supply immunization to helpless corners of the world, is itself confronting a genuine deficiency of the COVID-19 vaccine. There is another problem that is some countries are facing delays in receiving vaccines due to some reasons. So, they are delaying the booster dose administration that can seriously hamper the vaccination. In that case, a booster dose can be used from a different type of COVID-19 vaccine. That would solve the problem of delaying the second dose of the vaccine.

1.2Research Gap

Despite the fact that there is a priority for blending immunization types and there is a sound logical reason for doing as such, mRNA vaccines have just been endorsed interestingly for COVID-19. This implies we have no history of what happens when utilized in blend with adenovirus vectored vaccines. This is the reason analysts are calling for cautious examinations to test diverse vaccine mixes, giving extraordinary consideration not exclusively to their capacity to help resistance yet in addition to any extra possible incidental effects (Joi, 2021). This study finds that when mRNA vectored vaccine and adenovirus vectored vaccines are used in mixed doses there is no serious life-threatening side effects. No hospitalization is required for the patients that were administered with mRNA and adenovirus vectored vaccines doses.

1.3Objective

The objective of this study is to determine the effectiveness of the utilization of administering 2 doses of COVID-19 vaccines from two manufacturers. To see the usefulness of such vaccination some other topics are also discussed.

Objective 1: To outline the mechanism of action of different types of COVID-19 vaccines worldwide

Objective 2: To campaign the benefits of a heterologous mixture of COVID-19 vaccination.

Objective 3: To report the implementation of the heterologous mixture of COVID-19 vaccination in different countries worldwide.

1.4Significance of the study

This study finds the effectiveness of utilizing different types of vaccines as a heterologous booster dose. Such as AstraZeneca as the first dose and Pfizer/BNT as the second dose or Pfizer/BNT as the first dose, AstraZeneca as the subsequent dose. Some nations have authorized the Chinese manufactured vaccine Sinovac-Corona vaccine as the first dose and AstraZeneca ChAdox1 or Pfizer/BNT as the further dose. Utilizing second shots with a different type of vaccine has proven to be very effective in creating a better immune response. Mixed vaccination such as AstraZeneca as initial and subsequent boost with (mRNA) elevated Ig-G reactions, contrasted with rodent immunized with a single dose with one of the ChAdox1 or mRNAs, with a significant relationship between the two independent (ELISA) strategies. An increased amount of SARS-CoV-2 spike-explicit Immunoglobulin-M was identified in total immunized rodent populations, though heterologous immunization with saRNA-ChAdox1 developed higher serum SARS-CoV-2 spike-explicit Immunoglobulin-A levels contrasted with a single shot of vaccination with any of the vaccines (Spencer et al., 2021). The study performed at The University of Valld' Hebron Hospital stated that utilizing the Initial And subsequent booster dose with Biotech and Oxford combined vaccination appeared to enhance the immune response of the Oxford–AstraZeneca-dosed personnel's immune system (Callaway, 2021). Some of the Thailand citizens who were vaccinated with the Sinovac vaccine was also infected by the COVID-19 virus. Excess of 600 Thai clinical workers who were completely vaccinated with the Chinese-made vaccine Sinovac was infected with the COVID-19, which is presently common in the region of Southeast Asia. Among the 677,348 clinical staff who was given two dosages of the Chinese-created COVID-19 immunization, there were 618 positive cases between the months April to July as information showed by the government. There was a nurse among them who died and was also in a critical condition (Pietsch, 2021).

Chapter 2

Vaccine mechanism

A significant degree of killing antibodies against the corona virus is essential for an acting antiviral immunization for humans. Preparing and showing COVIID-19 epitopes by antigen-presenting cells employing human leukocyte antigen type I prompt actuation of CD8+ T cells that divide toward cytolysis effectors (cytotoxic T lymphocytes) which kill virus-containing cells. Figure-1 shows that initiation of T helper and CD4+ T cells through viral peptides introduced on Human Leukocytes Antigen type II alleles further upgrades the CD8+ T cell reaction while Leukocytes Antigen type Processing and showing of SARS-CoV-2 epitopes by antigen introducing cells using human leukocyte antigen type I prompts guidelines to CD8+ T cells which separates into cytolysis' effectors that kill cells containing the virus (Flanagan, et al., 2021).



Figure-1: Elements of the immune system against COVID-19 (Flanagan K., et al 2021)

2.1Types of available COVID-19 vaccines

2.1.1Vaccines Based on Full-Length S Protein

2.1.1.1Mechanism

NVX-CoV2373 is the vaccine manufactured by Novavax from recombinant technology by incorporating S protein in the Matrix-M1 that is Novavax's restrictive nanoparticle technology. Matrix M activates leukocyte relocation into the depleting lymph nodes (LN) that expands T cell as well as B cell as well as Natural Killer cells, and dendrites cells into Lymph nodes. A significant amount of S protein-specific antibodies can be delivered by the Novovax COVID-19 vaccine that can hinder ACE-2 RBD of humans also can also produces SARS-CoV-2 killing antibodies after the administration of a single dose of the vaccine (Belete, 2021).

2.1.1.2Effectiveness

A total of 15,187 members went through randomization, and 14,039 were the efficacy measuring group. Of the members, 27.9% were 65 years old and older, and 44.6% had co-existing diseases. Infection occurred in 10 members of the members who got the vaccine and in 96 members who got the placebo group, with an indication beginning of somewhere around seven days while taking the subsequent dose, with immunization adequacy of 89.7%. No hospitalizations or death reports have occurred among the 10 cases in the immunized group. Five instances of fatal disease accounted for were all in the placebo (Heath et al., 2021).

2.2.2Live-Attenuated Vaccines

2.2.2.1Mechanism

Crown Vac, produced by inactivated vaccine technology created by the country of China's one of the main vaccine producers, Sinovac COVID-19 immunization is designed in such a way that it can grow viruses inside cell culture, and virus cells are inactivated by using formalin with alum adjuvant. Inactivated COVID-19 viruses have been incorporated with the RBD into the S protein as safe activation. COVID-19 Vaccine was conceded a crisis use authorization by Chinese specialists prior to the inception of stage three investigations. Phase II clinical preliminary outcomes displayed it actuated neutralizing immunizers 14 days after the administration of the vaccine. The Sinovac Corona Vaccine showed greater than 90% efficacy in 600 healthy vaccine recipients and can induce an effective immunological reaction (Belete, 2021).

2.2.2.2Effectiveness

Sinovac: Sinovac's COVID-19 vaccine showed to be 100% efficient and effective in forestalling moderate infections, 77.9% successful in forestalling possible mild cases and represents general adequacy of 50.5% at recent trials in Brazil (Halim, & Halimand, & Tjhin, 2021.)

2.2.3mRNA Vaccine

2.2.3.1Mechanism

The mRNA vaccines are the first approved immunizations with a new strategy to prevent infection, starting a new era of preventive medication. (Vitiello, & Ferrara, 2021). Moderna has performed an enlarged parameter, the business fill-complete process of manufacturing

Moderna’s mRNA vectored COVID-19 immunization at Catalent's biologics office in the US. Additionally, it is moderately protected as it's an inactivated microbe. Bio N Tech (162b1 and b2) COVID-19 vaccine is an mRNA vaccine that encodes SARS-CoV-2 RBD and full-length spike separately (Belete, 2021). The mRNA is incorporated in 80 nm that can be converted into cationic lipid-based nanoparticles which can increment its conveyance (Belete, 2021).

2.2.3.2Effectiveness

Randomly 195 members were selected.12 members got immunization and 3 got placebo among 15 members of each of 13 groups. BioNtech162b2 was related to less occurrence and less systemic reaction than BioNTech162b1, especially among elderly populations. The two groups (young and older), both of the immunization applicants evoked comparable dose induced COVID-19 neutralizing mathematical mean titers, which were like or higher than the mathematical mean titer of a panel of SARS-COVID-19 convalescence blood specimens (Walsh et al., 2020). Pfizer- From the trial including total members of 21720, the vaccine receivers, ≥16 years got 30μg of this mRNA antibody managed in 2 dosages 21 days separated. Amidst 21720 vaccine receivers, 8 vaccine receivers displayed COVID-19 symptoms between the periods of a few weeks after taking a further dose of the vaccine regimens. BioNtech162b2 displayed a security level of 95%. Side effects included temporary pain at the injection site, weariness, and migraine was evaluated as an ordinary local response after injection. Less than 1% experienced serious pain at the spot of the injection (Halim, & Halimand, & Tjhin, 2021). Dose-dependent local adverse effects include migraine as well as myalgia, and temporary agony at the site of injection. Adverse effects were relatively low after the subsequent shot of the vaccine (Anderson et al., 2020).

2.2.4Replicating and Non-Replicating Viral Vectors Vaccines

2.2.4.1Mechanism

AstraZeneca (ChAdOX1) is a SARS-COVID-19 vaccine competitor that utilizes a non-repeating chimpanzee-based adenovirus vectored (ChAdOx1) immunization. This vaccine actuates the S protein from the SARS-COVID-19 virus. The adenovirus is modified genetically in such a way it doesn't clone inside cells. After administration of the vaccine, cells incite spike specific protein and produce a significant immune response to create killing antibodies that bind to spike glycoprotein and kill SARS-COVID-19 infection. Furthermore, AstraZeneca immunization prompts T-cells that can neutralize the affected cells. Side effects were reduced with 1 gm paracetamol for the initial 24 hours after vaccination. Two dosages were sufficient to initiate an adequate immunological response in every one of the members and had no life-threatening side effects (Belete, 2021).

2.2.4.2Effectiveness

ChadOx1-The Clinical trial stage 3 included the group of total 23 848 members. The efficacy of the AstraZeneca vaccine showed to be processed as 70.4%. This vaccine that is being vectored by adenovirus displayed of being viable and effective for battling COVID-19 as a total of 79 patients among 5807 ChAdOx1 immunization receivers displayed Corona virus infection symptoms (Halim, & Halimand, & Tjhin, 2021). There was an issue of blood clots regarding this vaccine. The information detailed in the MHRA weekly report up to 26 May 2021 estimates a general incident of a blood clot of around 13.6 per million after first or unknown doses of the AZ vaccine directed in the UK. The reported incident after the second dose is 1.3 per million dosages and all cases were in patients matured 50 years or older (Public Health England., 2021).

Sputnik V uses a non-cloning viral vector "adenovirus" containing gene explicit spike protein like other vaccines. The distinction with other vaccines is that Sputnik V uses two adenovirus vectors: Ad26 and Ad5, rather than a solitary serotype in the primary dose, Ad26 is allowed and, the second dose of Ad5 is given following 21 days (Belete, 2021).

Chapter 3

Benefits of mixing covid19 vaccines

Blending two distinct vaccines is nothing but another idea; priority exists for Ebola infection immunization trials. A decent antibody reaction against glycoprotein of Ebola was found while incorporating to a distinct type of Ebola immunization, regardless of sequence as well as the time gap between two administrations (Milligan et al., 2016). To rapidly immunize the people that are most vulnerable to the COVID-19 virus with an available dose of vaccines, a blend and match with vaccines that are available might be necessary.

3.1.1Better Immune Response

A study performed in Spain found that individual members who got an initial shot of AstraZeneca immunization then got a booster dose with Bio N Tech immunization had a better immune response than the individuals who got both dosages with AstraZeneca vaccine (Joi, 2021). Mice vaccinated with both RNA-based immunization and adenoviral incorporated immunization in opposition to corona virus. Antibody responses are higher in two dosages of mixed vaccine regimens than single-dose regimens. Neutralizing titers after heterologous first and subsequent doses were essentially similar or higher than the titers estimated after homologous prime-boost immunization with viral vectors. Critically, the cellular immune response after a heterologous vaccination is overwhelmed by cytotoxic T cells and Th1+ CD4 T cells, which is better than the reaction prompted in homologous vaccine regimens in mice (Spencer et al., 2021).

3.1.2 Increased level of antibody

The study in Spain found that individuals who got a first shot of the Oxford-AstraZeneca vaccine followed by a booster dose with the Pfizer-Bio N Tech vaccine appear to have had more immune response than the individuals who had two dosages of the AstraZeneca vaccine. Antibodies produced by Bio N Tech and AstraZeneca immunization productively kill the alpha variation, while the killing of gamma and beta variations is by all accounts diminished. In addition, the BNT vaccine demonstrated being thirteen and twenty-eight percent less defensive in opposition to the advancement of systematic variations for alpha and Beta, individually. Heterologous immunization with mixed ChAd0x1 and Bio N Tech vaccines promoted a profoundly critical 11.5-crease increment for counter-S Ig-G compared with a 2.9-overlap increment after homologous ChAdox1 immunization. Changes for counter -S Ig-A showing better immune protection reactions while providing heterologous initial and second dose vaccination. Counter S Immunoglobulin G and Immunoglobulin A amount after ChAdox1/BNT mixed immunization were inside the range of the total Bio N Tech/Bio N Tech vaccinated population (Barros-Martins et al. 2021).

3.1.3No potential risk of using vaccines from different sources

According to top specialists, the prolonged blending of various COVID-19 immunizations is probably not going to be unsafe – and could even give better insurance against the COVID-19 virus. Taking one sort of immunization today and a different dose by another maker a year down the line could become typical if the pandemic proceeds for quite a long time. With the vaccines delivered so far, a subsequent administration is essential after the primary dose further shot is hoped to support insurance. Prof Jones virologist from the UK said that if an individual finished two dosages of one immunization now, and took an alternate COVID-19 vaccine a year after the fact, there was probably not going to be any danger (Bardsley, 2021).

As indicated by a United Kingdom study, there can be more incidental effects related to blending immunization types contrasted with getting a similar vaccine for the two portions, Dr. Joss Reimer said in a question-answer session at the RBC Convention Center inoculation supersite, German and Spanish investigations didn't discover an expansion in incidental effects for blending vaccines types. So, it's confusing for us to finish up without a doubt about the side effects, since they have various outcomes in these examinations, and incidental effects are all moderately limited, she said. So, what we would say, now, is there's no specific information showing that there's any expanded danger related, even temporarily, with blending immunizations. Regardless of whether there is, those side effects are gentle, they settled totally. As far as a safe reaction, which Reimer said addresses long-term insurance from COVID-19, blending portions gives brilliant assurance (Snell, 2021).

3.2Covid19 Vaccine Shortage

Only four countries or regions that contain limited portions of the overall population have administered over two-thirds of all COVID-19 immunization dosages, regardless poorest nations have scarcely started vaccination because of the absence of financing and supply. The rich countries have secured a large part of the near-term supply. Just 20-25 % of the inhabitants will be brought under COVID-19 vaccination on the 92 poorest nations regardless of vaccination procedure. Vaccination of these countries may not complete 60% around 2023 or further at the current speed of vaccination (McClellan et al., 2021). As indicated by the Duke Global Health Innovation Center, nations have put an advanced order of aggregate of seven billion dosages of corona vaccine, 4 billion of them are supposed to go to the rich countries. In the end, top-income nations that comprise sixteen percent of the overall population have stored 65% of all COVID-19 vaccines (Choi, 2021). Director of World Health Organization Adhanom Ghebreyesus said, whereas each of every four individuals in

wealthy nations got an immunization, 1 of 500 individuals in poorest countries got a single shot (Hinnant, & Cheng, 2021). South Africa, being the continent's robust financial resources and its big COVID-19 patients, only less than one percent of individuals are completely immunized, as per an overall tracker kept by Johns Hopkins University as of 20th June 2020. What's more, a huge number of the country's healthy laborers, a considerable lot of whom encounter the virus consistently, are as yet waiting to be vaccinated with the first portion. Nigeria, having more than 200 million individuals, just point-one percent individuals is completely immunized. Kenya has 50 million individuals, and is almost unvaccinated. Uganda is taking dosages from its city-regions since it doesn't have enough dosages to vaccinate in large urban communities (Imray, 2021). India is one of the largest COVID-19 vaccine manufacturers facing a vaccine shortage. The nation's vaccine manufacturer Indian Serum Institution, the world's biggest immunization creator, was intended to supply the majority of the vaccines to the nation headed towards an eager objective - covering 250 million individuals by July. Around 26 million individuals are vaccinated fully out of 1.4 billion people, and 124 million have gotten a single dose. Leader Narendra Modi's administration has dropped sends out, reneging on global responsibilities. Sadly, vaccine stocks in the nation have almost evaporated, and nobody is sure when more will arrive (Alluri, 2021). According to May 5, 2021, around 30 million individuals got both doses of a COVID-19 vaccine in India information showed by the government. Simply more than 2% of India's total populace of 1.3 billion individuals — even though around a fourth of that absolute number are less than 15 years of age are not qualified for a vaccine yet. Dr. Chandrakant Lahariya, a doctor from New Delhi and vaccine scientist said Immunization supplies are probably not going to change radically, India requires around 200 to 250 million dosages monthly to work COVID-19 immunization and has about 70-80 million portions monthly. There is a long way to reach that kind of reserve, (Ellyatts, 2021). According to

DW.com Bangladesh is facing shortages of vaccines as exports are banned by India shortly. To guarantee that residents would get the COVID-19 vaccine on time, Bangladesh managed to sign a contract with the Indian Serum Institution to purchase 30 million dosages of immunization. As indicated by the agreement, Dhaka should have 5 million doses per month from January to June in 2021. In any case, it just got 7 million portions. Specialists dread that decision of India to stop the export of covid19 immunization can danger Bangladesh's program for COVID-19 immunization. The USA and Europe have brought a large extent of Corona vaccines and affluent Western nations have held most of the underlying corona vaccine dosages delivered, poor and low-middle-income countries are being neglected and deprived of corona vaccination. Blending various brands of vaccines against a similar microorganism isn't unprecedented for routine vaccination. At this time of providing COVID-19 immunization is uncertain as well as dispensation is difficult, blending and utilizing vaccines can provide additional functional adaptability amid vulnerability (Choi, 2021).

Chapter 4

Countries issued mixing of vaccines

The following countries have issued the recommendation for mixing vaccine doses. Most of these countries do not have the COVID-19 vaccine manufacturing facilities.

4.1Germany

Germany has given strong recommendations in the world to provide mixed vaccine doses of two distinct brands. According to Committee on vaccination, the individuals who got an initial portion of immunization by Oxford ought to take mRNA immunization as their subsequent dose, no matter their age. Germany is a top nation to suggest that persons who got an initial shot of AstraZeneca get either a vaccine developed by Bio N Tech or Moderna as a subsequent portion of the vaccine (Kennedy, & Pleitgen, & Gumbrecht, 2021).

4.2 Canada

Individuals who got the initial portion of the AstraZeneca corona vaccine ought to be presented with a further shot of a similar item, or one of the Pfizer or Moderna doses, as indicated by new guidance provided by Canada's Committee on vaccination. The Bio N Tech and Moderna’s vaccines, which utilize a similar mRNA-based vaccine, can likewise be utilized conversely when having limited access to vaccines. Some provinces in Canada had effectively declared they will provide the people with Oxford’s vaccination alternative to get a Pfizer or Moderna as a choice as a subsequent dose (Duong, 2021).

4.3Thailand

Thailand will utilize AstraZeneca immunization as a second dose for the individuals who accepted Sinovac's shot as their first dose in a bid to enhance immunity, the move is the

principal openly declared blend and match of a Chinese vaccine and a Western-developed vaccine, as a new strategy. This is to further develop insurance against the Delta variation and assemble a significant degree of invulnerability against the COVID-19 virus, health minister Anutin Charnvirakul said, adding that the second dose of AstraZeneca would come three or a four after the principal Sinovac shot (Thepgumpanat, & Wongcha-um, 2021).

4.4 Spain

The Spanish minister of health declared on May 19 that the nation would permit the people aged less than sixty years, who had an AstraZeneca initial dose, to get a second shot of one of the AstraZeneca or Pfizer's immunization.

4.5 USA

The US, In January USA, declared the permission of a blend of Pfizer/BioNTech's and Moderna's immunization with 28 days of gap between two subsequent doses, in reasonable situations.

4.6 Bahrain

Bahrain permitted the authorization of mixing of COVID-19 vaccines announcing on the 4th June declared that applicants could get a booster dose with either of the Bio N Tech or Sinopharm immunization, paying little mind to which shot they had at first taken.

4.7 Some other Countries

Bhutan, Italy, and UAE have begun mixing vaccines, with priority doses offered to healthcare workers and frontline staff, after it was observed that the efficacy of current doses did not withstand well against the spreading variants.

Table-1: List of countries have allowed mixing vaccines and the brands from which initial and second dose can be used

Country	**First dose**	**Second dose**
Germany	AstraZeneca	Pfizer/Modera
Canada	AstraZeneca	Pfizer/Moderna
Spain	AstraZeneca	Pfizer
Thailand	Sinovac	AstraZeneca/Pfizer/Moderna
USA	Pfizer	Moderna
Bahrain	AstraZeneca	Pfizer/Sinovac

Chapter 5

Discussion

6.1Mixing COVID-19 vaccines

Blending various brands of vaccines against a similar microorganism isn't unprecedented for routine vaccination. Some trials are performed by scientists to check whether vaccine mixing against COVID-19 would give similar resistance as the complete two-dose regimens. Such mixing includes first dose of the Bio N Tech mRNA vaccine followed by the second dose of AstraZeneca adenoviral incorporated vaccine or first dose of AstraZeneca adenoviral incorporated vaccine and second dose of the Bio N Tech mRNA vaccine (Choi, 2021). Scientists of the UK have performed a trial that blended and utilized two different types of COVID-19 vaccination to complete vaccination to a large number of individuals and provide potent immune resistance to all groups of people. Almost all COVID-19 vaccines are designed as two dose regimens 'prime' dose later a 'booster dose' to generate cells known as memory cells and enhance the immunological response. Clinical examination will check members' safe reactions to getting the first dose of a COVID-19 vaccine delivered by United Kingdom’s Oxford University, and medication manufacturer AstraZeneca which utilizes a vaccine infection to convey a key COVID-19 quality inside cells than a second portion of the immunization by Pfizer drug manufacturing company, which utilizes mRNA incorporated immunization to develop an immunological response. Oxford examiners performed the study, vaccine engineers combined two vaccines to battle the same virus, and specialists are quick to convey the procedure known as a heterologous prime-boost against the COVID-19 (Ledford, 2021).

6.2New Variants

The alpha variant is far more transmissible than the Wuhan variant and is 70% more contagious than the standard corona variant (Duong, 2021). Delta variant is the name for the B.1.617.2. Variation, a COVID-19 transformation surfaced in India. In December of 2020, Delta cases were identified, and the strain spread fast in India and afterward in Great Britain (WHO.INT). The Delta variant spread more rapidly and was the reason for more death than the standard COVID-19 virus found in Wuhan.

The Lambda variation, specialists in Chile presume that the lambda COVID-19 variation isn't just more irresistible than corona virus could likewise overwhelm vaccines. The lambda variant was identified in Chile. The primary case in the United States has been spotted at Houston Methodist Hospital. A COVID-19 variation that ends up being resistant to antibodies keeps clinical specialists, public health officials, and medical services experts including infection prevention personnel on the frontline of the Corona war up at night. There is no serious alarm yet but quite possibly the alert might need to be sounded sooner or later about the lambda COVID-19 variation shortly. A preprint study by experts in Chile proposes that the mutation, which initially surfaced in Peru about a year prior and is highly contagious, may be able to dodge the COVID-19 vaccine antibodies (Diamond, 2021). The primary reason to blend vaccines is to initiate a more extensive immune reaction. However, there should be a logical and administrative avocation to mix vaccines. According to Dr. Martinon various variants that arose in the country UK, and Brazil, as well as South Africa, and later in India, are now confronting a storm of infection and another COVID-19 change that is possibly making COVID-19 additional infectious as well as more contaminant. Utilizing vaccines from different types would provide better and increased safety and challenge for a new variation of COVID-19 to infect or stop the rise of new variants, as Dr. Martinon quotes.

After the vaccination of initial and subsequent dose with the ChAdox1 immunization and mRNA immunization. One-fifth of the portion for humans was utilized in the investigation. Fourteen days after vaccination the neutralizing antibody levels were estimated. The GMT of the ChaAdox1 was greater than mRNA/mRNA was more than the ChAdox1 group, as contrasted with the ChAdox1 group and the 2 × mRNA population. Like what we saw over, the ChAd0x1 vaccine prime, trailed by an mRNA immunization help (ChAdox1 > mRNA), actuated a fundamentally higher neutralizing antibody reaction than the 2 × mRNA immunization, with a GMT of 25,186 ($p < 0.01$) in the pseudo virus assay. Although the measure of binding antibody induced by mRNA > ChAdox1 was comparable to that incited by the ChAdox1 > mRNA, the neutralizing antibody reaction was fundamentally lower than ChAdox1 > mRNA (He et al., 2021).After utilizing Hannover Medical School's COVID-19 contact study associate of medical care experts to screen ChAdOx1 prepared immune feedback previously and three weeks after booster with ChAdox1 or Bio N Tech/Pfizer's BNT162b2.When examining the two vaccines boosted prime-actuated resistance, BNT instigated fundamentally higher frequencies of Spike specific CD4 and CD8 T cells and, specifically, high titers of killing antibodies against the Alpha, Beta, and the Gamma variations. Booster vaccination with BNT prompted killing antibodies at high frequencies against all examined varieties of concern of COVID-19 viruses including Alpha, Beta, and the Gamma were all variations of concern (VOC).

Every member had killing antibodies against the Alpha and Gamma variant, except two members had killing antibodies against the Beta variation (Barros-Martins et al., 2021).

6.3Second Dose for patients that has recovered

In the mRNA-1273 immunization stage 3 trials, 2.2% of vaccines had proof (serologic, virologic, or both) of SARS-CoV-2 infection at baseline, however, no subgroup examination was reported. The first dose leads to antibody levels comparable to the ones achieved after two doses in naïve vaccines, with strong correlations between T helper cells and antibody immunity to patients that have recovered. Of interest, SARS-CoV-2- infected people that had recovered, had a critical immune response after the first dose with no expansion in circulating antibodies or antigen-explicit memory B cells after the booster dose. All things considered, the immune reaction one week after the second dose of BNT162b2 in convalescents shows a decrease in both antibody levels and ELISA Spot-responsive T lymphocytes..

6.4Individuals Receive Only 1 Dose

The Pfizer and Moderna immunization studies included two doses of vaccines separated by either three weeks or four weeks. Members who had the initial dose delivered a vigorous neutralizer reaction as the second dose of vaccination. Presently, there isn't any proposal for only the initial portion for patients who had an earlier disease to finish the vaccine regimen is essential because of worry for the development of new strains of COVID-19 variants. In a report that assessed the safe reaction to the initial dose after administration of the vaccine to the patients that have recovered from an infection, investigators found high levels of antibodies comparable to the persons who had no record of COVID-19 contamination after initial and subsequent doses. This kind of study shows that a single portion of the vaccine may be adequate for the patients who had recently recovered from corona virus infection who have effectively produced enough protection against the contamination. Until more information is accessible, every individual who gets the accessible mRNA immunizations should get two dosages (Rio, & Malani, 2021).

6.5 Booster dose for elderly people

The member of joint committee on vaccination and immunization in UK Anthony Harnden quoted that the requirement booster dose is a must either to ensure against another variation, as the guarantee of protection is unknown (Mahase, 2021). As changes occurred in immunological systems due to age related issues, suggested that older people generally don't produce adequate defensive immunity after vaccination. So, the adequate and promising result should have come after the clinical trial. In order to determine the relative amount antibody produced after injection with ChAdOx1 nCoV-19 (AstraZeneca) COVID-19 vaccine in young and older people to determine antibody production amount in relation to young and older mice Both young and aged mice were injected subsequently with lone dose of adenoviral vector ChAdOx1 nCoV-19 (AstraZeneca) Covid19 vaccine. Spike-particular Th1 cells, poly-functional spike- particular CD8+ T cells as well as, B-delivering CD8 effectors produced by single dose of vaccination. Spike-identifying immunoglobulin-G and, Immunoglobulin -M are created from both the early extra follicular immunological response and the T follicular helper cell-upheld germinal central response, which is related to creation of microorganisms such as virus neutralizing antibodies. A second dose of such vaccination increments the immune response in older mice (Cayetano et al., 2021).

Chapter 6

Limitations

Combining vaccination doses from various manufacturers has very rarely been approved for other diseases in the past. It is because of the way vaccine research is funded. Some governments have announced that certain patients would be given a different COVID-19 shot the second time around. When a rare blood clotting issue was discovered in a small fraction of younger AstraZeneca vaccination users, some governments were unwilling to require that everyone who had had the first dose should also receive the second. Snap said of the Com-COV experiments, ‘this is what we expected when we wanted to generate data’. People who have already received an AstraZeneca dosage might choose to finish the series with an mRNA vaccine if they desire.

7.1 Future recommendation

The results of a clinical trial that could influence how COVID-19 vaccinations are used in the United States in the future will be presented to an expert committee that advises the Centers for Disease Control and Prevention.

The National Institute of Allergy and Infectious Diseases is a conducting-mixing trial, in which the COVID-19 vaccines approved in the United States are tested in conjunction with one another. The trial's purpose was to explore if employing a different vaccination as a booster shot would increase protection.

After receiving a single dosage of Johnson & Johnson's vaccination, does receiving a dose of Pfizer vaccine result in the creation of more antibodies than receiving a second dose of J&J's vaccine? Is it true that Pfizer and Moderna's messenger RNA vaccines are nearly interchangeable, or does switching even provide a greater range of immune responses?

We must recognize, according to Michael Osterholm, director of the Minnesota University Center for Infectious Diseases Research and Policy, that many questions about the use of vaccinations remain unanswered. The most effective period between doses is unknown. We don't know how many doses we'll need, and we don't know if mixing up the immunizations each person gets will provide better long-term protection. We're still in the early stages of figuring out how to employ COVID-19 vaccinations, according to Osterholm, who added that now that we have effective vaccines, we need to start working out how to effectively use them. We need to start thinking about decisions in terms of public health.

Chapter 7

Conclusion

Different types of COVID-19 vaccines such as mRNA-based, adenovirus vectored vaccines, replicating, and non-replicating viral vectored vaccines, live attenuated vaccines are designed to target different parts of the COVID-19 virus. Utilizing two distinct types of vaccines should be very useful to fight the virus. While using two distinct types of vaccines as a prime and subsequent booster dose produces better immunological response and a higher amount of neutralizing antibody to neutralize the COVID-19 virus as proven by research. Scientists from Germany performed the safety of utilizing two different brand vaccines, as booster dose, 9 weeks from the initial dose showed fewer side effects about the same types of vaccine as both prime and booster dose. But a study in England showed that the side effects were relatively higher in terms of heterologous vaccination. This might happen because the booster dose was used 4 weeks after the initial dose. In both studies, no serious side effects were observed and no hospitalization was required for most of the side effects such as fever, myalgia, and headache were gone after taking paracetamol. In this ongoing COVID-19 pandemic some countries are facing vaccine shortages. Some richest nations are storing vaccines for future usage and some African poor countries have not got enough vaccines to complete the first dose of vaccines. Almost 90% of African nations are set to miss the worldwide objective of immunizing 10% of their kin by September, as per the World Health Organization. One serious issue is that COVAX, the UN-sponsored undertaking to supply immunization to helpless corners of the world, is itself confronting a genuine deficiency of the COVID-19 vaccine. Some countries have administered the first dose of the vaccine but don’t have enough of the same brand of vaccine to complete two-dose regimens. On the other hand, the new and more deadly COVID-19 variants have brought about total lockdown to

some countries. These new variants have been proven more deadly than the standard COVID-19 variants such as gamma delta and lambda variants. If two types of vaccines are used as a prime and booster dose, the immunological system can produce enough antibodies to kill these new variants. So, it has been a dire need to vaccinate as many people as possible. To achieve this goal using a booster dose with different types of vaccine can be very useful to avoid vaccine shortages and complete two-dose regimens of the COVID-19 vaccine. Some countries have already issued orders to use different brands of vaccine as a prime-boost vaccination as a booster dose. So, such heterologous prime-boost vaccination can be very useful to fight vaccine shortage and also can work as a new weapon to fight off new, more contagious and more deadly COVID-19 variants.

References:

Alluri, A. (2021). Why COVID-19 vaccine producer India faces major shortage of doses. Retrieved August 6, 2021, from https://www.cnbc.com/2021/05/05/why-covid-vaccine-producer-india-faces-major-shortage-of-doses.html

Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., McDermott, A. B., Flach, B., Lin, B. C., Doria-Rose, N. A., O'Dell, S., Schmidt, S. D., Corbett, K. S., Swanson, P. A., Padilla, M., … Beigel, J. H. (2020). Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. *New England Journal of Medicine, 383* (25), 2427–2438. https://doi.org/10.1056/nejmoa2028436

Baden, L. R., elSahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., … Zaks, T. (2021). Efficacy and safety of the mRNA- 1273 SARS-CoV-2 Vaccine. *New England Journal of Medicine, 384* (5), 403–416. https://doi.org/10.1056/nejmoa2035389

Bardsley, (2021). No long-term risk from mixing Covid-19 vaccines, scientists say. *The national news*. Retrieved August 28, 2021, from https://www.thenationalnews.com/uae/health/no-long-term-risk-from-mixing-covid-19-vaccines-scientists-say-1.1144800

Barros-Martins, J., Hammerschmidt, S. I., Cossmann, A., Odak, I., Metodi ., Stankov., Morillas, G., & Behrens M. (2021). Humoral and cellular immune response against

SARS-CoV-2 variants following heterologous and homologous ChAdOx1 nCoV-19/BNT162b2vaccination., *Med Rxiv* doi: https://doi.org/10.1101/2021.06.01.21258172

Belete, T. M. (2021). Review on up-to-date status of candidate vaccines for COVID-19 disease. *Infection and Drug Resistance* (Vol. 14, pp. 151–161). Dove Medical Press Ltd. https://doi.org/10.2147/IDR.S288877

Callaway, E. (2021*).* MIXING COVID VACCINES TRIGGERS POTENTIMMUNE RESPONSE Preliminary trial results show the benefits of combining different vaccines. *Nature* Vol 593 page 491.

Choi, E. M. (2021). COVID-19 vaccines for low- and middle-income countries. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, *115*(5), 447–456. https://doi.org/10.1093/trstmh/trab045

COVID*:* Bangladesh faces vaccine shortage as India halts exports | Asia | an in-depth look at news from across the continent | *DW* | *14.04.2021*. Retrieved August 6, 2021, from https://www.dw.com/en/bangladesh-india-coronavirus-vaccine/a-57200281

Del Rio, & Malani, (2021). COVID-19 in 2021-Continuing Uncertainty. In *JAMA - Journal of the American Medical Association* (Vol. 325, Issue 14, pp. 1389–1390).

Diamond, F. (2021). Lambda Variant of COVID-19 Might Be Resistant to Vaccines,

Duong, D. (2021). Feds sign off on mixing and matching COVID-19 vaccines, but evidence gaps remain. In *Canadian Medical Association Journal*, *193*(25), E967–E968. https://doi.org/10.1503/cmaj.1095946

Ellyatts, (2021). Why COVID-19 vaccine producer India faces major shortage of doses. In *CNBC*. Retrieved August 6, 2021, from https://www.cnbc.com/2021/05/05/why-covid-vaccine-producer-india-faces-major-shortage-of-doses.html

Explained: Which are the countries allowing you to mix Covid-19 vaccines? *The Indian Express*. (2021). Retrieved August 6, 2021, from https://indianexpress.com/article/explained/coronavirus-vaccination-mixing-matching-shots-7340869/

Five things to know about: Mixing and matching corona virus vaccines | Research and Innovation. (2021). Retrieved August 8, 2021, from https://ec.europa.eu/research-and-innovation/en/horizon-magazine/five-things-know-about-mixing-and-matching-coronavirus-vaccines

Flanagan, K. L., Best, E., Crawford, N. W., Giles, M., Koirala, A., Macartney, K., Russell, F., Teh, B. W., & Wen, S. C. H. (2020). Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines. In *Frontiers in Immunology* (Vol. 11). Frontiers Media S.A. https://doi.org/10.3389/fimmu.2020.579250

Focosi, D., Baj, A., & Maggi, F. (2021). Is a single COVID-19 vaccine dose enough in convalescents? In *Human Vaccines and Immunotherapeutic*. Bellwether Publishing, Ltd. https://doi.org/10.1080/21645515.2021.1917238

Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., Dold, C., Faust, S. N., Finn, A., Flaxman, A. L., Hallis, B., Heath, P., Jenkin, D., Lazarus, R., Makinson, R., … Yau, Y. (2020). Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. *The Lancet*, *396*(10249), 467–478. https://doi.org/10.1016/S0140-6736 (20)31604-4

Halim, M. (2021). COVID-19 Vaccination Efficacy and Safety Literature Review. In *Journal of Immunology and Allergy*. Retrieved from- https://doi.org/10.37191/mapsci-2582-4333-3(1)-058

He, Q., Mao, Q., an, C., Zhang, J., Gao, F., Bian, L., Li, C., Liang, Z., Xu, M., & Wang, J. (2021). Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. *Https://Doi.Org/10.1080/22221751.2021.1902245*, *10* (1), 629–637. https://doi.org/10.1080/22221751.2021.1902245

Heath, P. T., Galiza, E. P., Baxter, D. N., Boffito, M., Browne, D., Burns, F., Chadwick, D. R., Clark, R., Cosgrove, C., Galloway, J., Goodman, A. L., Heer, A., Higham, A., Iyengar, S., Jamal, A., Jeanes, C., Kalra, P. A., Kyriakidou, C., McAuley, D. F., … Toback, S. (2021). Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. In *New England Journal of Medicine*. https://doi.org/10.1056/nejmoa2107659

Hillus, D., Tober-Lau, P., Hastor, H., Helbig, E. T., Lippert, L. J., Thibeault, C., Solarek, A., von Kalle, C., Corman, V. M., Kopankiewicz, P., Suttorp, N., Bias, H., Seybold, J., Kurth, F., & Sander, L. E. (2021). *Reactogenicity of homologous and heterologous prime-boost immunisation with BNT162b2 and ChAdOx1-nCoV19: a prospective cohort study*. https://doi.org/10.1101/2021.05.19.21257334

Hinnant, & Cheng, (2021). |Covid-19 vaccine shortages hit 60 poor countries in shocking imbalance. In *Business Standard News*. Retrieved August 6, 2021, from https://www.business-standard.com/article/international/covid-19-vaccine-shortages-hit-60-poor-countries-in-shocking-imbalance-121041100070_1.html

Hung, I. F. N., & Poland, G. A., (2021). Single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster. *The Lancet*, *397* (10277), 854–855. https://doi.org/10.1016/S0140-6736 (21) 00528-6

Imray, G. (2021). "This IS INSANE": Africa desperately short of COVID vaccine.*APNEWS*. Retrieved August 6, 2021, from https://apnews.com/article/uganda-

south-africa-cape-town-africa-coronavirus-pandemic-c5d7c2b0f927c8bd4d8d91fbf2cda1ea

Joi, P. (2021), Is it safe to mix and match COVID-19 vaccines, Gavi, the Vaccine Alliance. Retrieved August 3, 2021, from https://www.gavi.org/vaccineswork/it-safe-mix-and-match-covid-19-vaccines

Kennedy N. & Pleitgen F. & Gumbrecht J. (2021). Germany issues world's strongest recommendation for mixing Covid-19 vaccines.*CNN*. Retrieved August 6, 2021, from https://edition.cnn.com/2021/07/02/health/germany-covid-vaccines-mixing-intl/index.html

Krause, P. R., & Gruber, M. F. (2020). Emergency Use Authorization of COVID-19 Vaccines — Safety and Efficacy Follow-up Considerations. *New England Journal of Medicine*, 383 *(*19), e107. https://doi.org/10.1056/nejmp2031373

Landau M. (2021). Should you mix and match COVID-19 vaccines? Experts weigh in.*Science*. Retrieved October 27, 2021, from https://www.nationalgeographic.com/science/article/should-you-mix-and-match-covid-19-vaccines-experts-weigh-in

Ledford, H. (2021). COVID vaccines and blood clots: five key questions. *Nature*, *592*(7855), 495–496. https://doi.org/10.1038/D41586-021-00998-W

Mahase, E. (2020). Covid-19: Pfizer vaccine efficacy was 52% after first dose and 95% after second dose, paper shows.*BMJ (Clinical Research Ed.)*, *371*, m4826. https://doi.org/10.1136/bmj.m4826

Mahase, E. (2021). Covid-19: Booster dose will be needed in autumn to avoid winter surge, says government adviser. In *BMJ (Clinical research Ed.)* (Vol.372, p.n664). NLM (Medline). https://doi.org/10.1136/bmj.n664

Mahase, E. (2021). Covid-19: Vaccine brands can be mixed in "extremely rare occasions," says Public Health England.*BMJ (Clinical Research Ed.)*, *372*, n12. https://doi.org/10.1136/bmj.n12

Mcclellan, M., Uday Kumar, K., Merson, M., & Edson, G. (2021). Reducing Global COVID Vaccine Shortages: New Research and Recommendations for US Leadership.

Milligan, I.D., Gibani, M.M., Sewell, R., Clutterbuck, E.A.,Campbell, D., Plested, E., et al. (2016) Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial. JAMA 315: 1610–1623

nCoV-19/ BNT162b2 vaccination. *MedRxiv* doi: https://doi.org/10.1101/2021.06.01.21258172

Normark, J., Vikström, L., Gwon, Y.-D., Persson, I.-L., Edin, A., Björsell, T., Dernstedt, A., Christ, W., Tevell, S., Evander, M., Klingström, J., Ahlm, C., &Forsell, M. (2021). Heterologous ChAdOx1 n CoV-19 and mRNA-1273 Vaccination. In *New England Journal of Medicine*, *385* (11), 1049–1051. https: //doi.org/10.1056/NEJMC2110716

Shaw, R. H., Stuart, A., Greenland, M., Liu, X., Van-Tam, J. S. N., & Snape, M. D (2021). Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. *The Lancet*, *397* (10289), 2043–2046. https://doi.org/10.1016/S0140-6736 (21) 01115-6

Silva-Cayetano, A., Foster, W. S., Innocentin, S., Belij-Rammerstorfer, S., Spencer, A. J., Burton, O. T., Fra-Bidó, S., le Lee, J., Thakur, N., Conceicao, C., Wright, D., Barrett, J., Evans-Bailey, N., Noble, C., Bailey, D., Liston, A., Gilbert, S. C., Lambe, T., &

Linterman, M. A. (2021). A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice. *Med,2* (3) ,243-262.e8. https://doi.org/10.1016/j.medj.2020.12.006

Snell J. (2021). Low risk to mixing COVID-19 vaccines, says Reimer. *WINNIPEG SUN*. https://winnipegsun.com/news/news-news/low-risk-to-mixing-covid-19-vaccines-says-reimer

Spencer, A. J., McKay, P. F., Belij-Rammerstorfer, S., Ulaszewska, M., Bissett, C. D., Hu, K., Samnuan, K., Blakney, A. K., Wright, D., Sharpe, H. R., Gilbride, C., Truby, A., Allen, E. R., Gilbert, S. C., Shattock, R. J., &Lambe, T. (2021). Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice.In *Nature Communications*, *12* (1). https://doi.org/10.1038/s41467-021-23173-1

Stankov ., Morillas., & Behrens, (2021). Humoral and cellular immune response against SARS-CoV-2variants following heterologous and homologous ChAdOx1

The Lambda Variant of the Corona virus: What You Should Know : Coronavirus Updates. (2021). *NPR*. Retrieved August 6, 2021, from https://www.npr.org/sections/coronavirus-live-updates/2021/07/22/1019293200/the-lambda-variant-coronavirus-what-you-should-know

ThepgumpanatPanu., & Wongcha-um, (2021). In first, Thailand to mix Sinovac, AstraZeneca vaccine doses | *Reuters*. Retrieved August 6, 2021, from https://www.reuters.com/world/asia-pacific/thailand-starts-tighter-coronavirus-lockdown-around-capital-2021-07-12/

Vitiello, A., & Ferrara, F. (2021). Brief review of the mRNA vaccines COVID-19. *In flammopharmacology*, 29 *(*3), 645–649. https://doi.org/10.1007/s10787-021-00811-0

Vogel, G. (2021). Mixing vaccines may boost immune responses. In *Science* (Vol. 372, Issue 6547, p. 1138). American Association for the Advancement of Science. https: //doi.org/10.1126/science.372.6547.1138

Walsh, E. E., Frenck, R. W., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., Swanson, K. A., Li, P., Koury, K., Kalina, W., Cooper, D., Fontes-Garfias, C., Shi, P.-Y., Türeci, Ö., Tompkins, K. R., … Gruber, W. C. (2020). Safety and Immunogenicity of Two RNA- Based COVID-19 Vaccine Candidates. *New England Journal of Medicine*, *383* (25), 2439–2450. https://doi.org/10.1056/nejmoa2027906

Wijerathana D. (2021). Can you mix COVID-19 vaccines? - *newscerca*. Retrieved August 3, 2021, from https://newscerca.com/can-you-mix-covid-19-vaccines/